Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Trading 0.2% Higher – Here’s Why

Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) were up 0.2% during trading on Friday . The company traded as high as $10.69 and last traded at $10.7140. Approximately 191 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 28,144 shares. The stock had previously closed at $10.69.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences currently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

The firm has a 50 day simple moving average of $10.69 and a two-hundred day simple moving average of $10.66.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Clear Street Group Inc. bought a new position in Oaktree Acquisition Corp. III Life Sciences in the third quarter valued at about $231,000. Rangeley Capital LLC grew its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% during the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after purchasing an additional 21,156 shares during the last quarter. Radcliffe Capital Management L.P. bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter valued at approximately $856,000. UBS Group AG increased its position in Oaktree Acquisition Corp. III Life Sciences by 987,110.0% during the 3rd quarter. UBS Group AG now owns 98,721 shares of the company’s stock worth $1,038,000 after purchasing an additional 98,711 shares in the last quarter. Finally, DLD Asset Management LP increased its position in Oaktree Acquisition Corp. III Life Sciences by 0.9% during the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares in the last quarter.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.